Aarti Pharmalabs (AARTIPHARM) | Stock Overview & Key Data
Aarti Pharmalabs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹971.00 on July 16, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aarti Pharmalabs
AARTIPHARM
|
62.82B Mid-cap | 5.66% | -9.99% | 1.80% | -15.40% | -13.91% | -27.61% | 62.73% | 147.07% | 147.07% | 147.07% | 147.07% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | 1.12% | -4.39% | 20.53% | -2.62% | -1.58% | -18.17% | 77.37% | -2.17% | -2.17% | -2.17% | -2.17% |
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
|
Natco Pharma
NATCOPHARM
|
191.91B Mid-cap | -2.38% | -29.31% | -10.42% | -6.36% | -4.57% | -5.35% | 37.05% | -21.16% | 69.86% | 1,522.04% | 4,430.15% |
Ownership & Short Interest
Calculate Your Aarti Pharmalabs Investment Returns
Long-Term Investment Performance Analysis
Aarti Pharmalabs stock price in Jan 2023 was ₹259.50, A ₹1,000.00 lump sum investment in Aarti Pharmalabs made 3 years ago would be worth approximately ₹2,468.79 today, representing a strong return of 146.88%. This translates to an annualized return (CAGR) of 30.73%.
3 Years 4 Months Investment Scenario (Jan 2023 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AARTIPHARM's 52-week high and low?
- In the last 52 weeks, Aarti Pharmalabs reached a high of ₹971.00 (on N/A) and a low of ₹585.00 (on March 30, 2026).
- What is the market cap and P/E ratio for AARTIPHARM?
- Curious about Aarti Pharmalabs's size and valuation? Its market capitalization stands at 62.82B. When it comes to valuation, the P/E ratio (trailing twelve months) is 29.41, and the forward P/E (looking ahead) is N/A.
- Does AARTIPHARM pay dividends? If so, what's the yield?
- Yes, Aarti Pharmalabs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.55%, and the company has paid an average of ₹3.17 per share annually over the past 3 years.
- Who are Aarti Pharmalabs's main competitors or similar companies to consider before investing?
When looking at Aarti Pharmalabs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Piramal Pharma
PPLPHARMA199.68B Healthcare Drug Manufacturers - Specialty & Generic -18.17% 77.37% Eris Lifesciences
ERIS193.36B Healthcare Drug Manufacturers - Specialty & Generic -21.75% 112.96% Natco Pharma
NATCOPHARM191.91B Healthcare Drug Manufacturers - Specialty & Generic -5.35% 37.05% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aarti Pharmalabs Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Aarti Pharmalabs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.69%, the Debt to Equity ratio from the most recent quarter is 32.97, and its Gross Profit Margin stands at 60.06%.
- What is the recent revenue and earnings growth for AARTIPHARM?
- Looking at Aarti Pharmalabs's growth, its revenue over the trailing twelve months (TTM) was INR18B. Compared to the same quarter last year (YoY), quarterly revenue grew by -19.60%, and quarterly earnings saw a YoY growth of -35.20%.
- How much of AARTIPHARM stock is held by insiders and institutions?
- Wondering who owns Aarti Pharmalabs stock? Company insiders (like executives and directors) hold about 42.62% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 12.01%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.